| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 221.2 | 196.5 |
| Gross profit | 158.2 | 137.3 |
| Profit before tax | -7.5 | -28.5 |
| Net income | -5.5 | -28.6 |
| EPS (diluted, $ a share) | $-0.03 | $-0.19 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +12.6% |
|---|---|
| Gross margin | 71.5% |
| Operating margin | 1.5% |
10-Q filed with the SEC, NASDAQ: ATEC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Alphatec Holdings, Inc.: key numbers
- Share price
- $6.78Close, Nov 16
- Market cap
- $1.05B
- Shares outstanding
- 155.14MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Alphatec Holdings, Inc.
All →Alphatec Holdings Director Keith Valentine Buys $243K of Stock
Keith Valentine, Director, bought 35,000 shares of Alphatec Holdings, Inc. at $6.93 a share, worth $243K in total on Nov 10, 2026. Shares held after the trade: 299,283 (+13.2%).
- Value
- $243K
- Shares
- 35,000
- Price
- $6.93
- Role
- Director
- Holding change
- +13.2%
- Trade date
- Nov 10, 2026
Alphatec Holdings Director David M. Demski Buys $409K of Stock
David M. Demski, Director, bought 60,000 shares of Alphatec Holdings, Inc. at $6.81 a share, worth $409K in total on Oct 30, 2026. Shares held after the trade: 491,635 (+13.9%).
- Value
- $409K
- Shares
- 60,000
- Price
- $6.81
- Role
- Director
- Holding change
- +13.9%
- Trade date
- Oct 30, 2026
Alphatec Holdings Financial Results
Alphatec Holdings reported Q3 2026 total revenue of $221 million, a 13% increase year-over-year, driven by 17% growth in surgical hardware revenue. Despite strong case volume growth of 20%, the company lowered its full-year 2026 revenue guidance to $862 million due to lower-than-expected biologics attachment.
- Term
- Q3 2026
“Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment. We own and are addressing that shortfall, and going forward, improving biologics performance is a clear priority for us. At the same time, we continued to see very strong demand for our procedural solutions, with hardware revenue growing 17%, case volumes growing approximately 20%, and new surgeon adoption increasing 25%.”
Pat Miles, Chairman and Chief Executive Officer